Skip to main content

Non-Antibiotic UTI Prevention

Non-antibiotic strategies can reduce reliance on daily antibiotics in selected patients with recurrent UTI. The AUA/CUA/SUFU 2025 guideline, WikiGuidelines 2024 consensus, and AGS Beers alternatives document support individualized prevention.[43][2][3] AUA/CUA/SUFU 2025 and EAU 2026 differ in tone on several agents (see the comparison table below), so state which guideline is being followed when counseling.[4] Network meta-analysis combines heterogeneous populations and indirect comparisons.[4]

This article is the prescribing-detail deep-dive for each modality. For the prevention decision framework, see UTI suppressive & prophylactic therapy; for treatment of active infection, see UTI treatment antibiotics.

Vaginal estrogen​

NICE NG112 (December 2024) advises considering vaginal estrogen when hygiene measures alone have not worked, reviewing it within 12 months, and not offering systemic hormone therapy solely to prevent recurrent UTI.[53] AUA/CUA/SUFU 2025 (statement 20): clinicians should recommend vaginal estrogen in peri- and postmenopausal women with rUTI when there is no contraindication . EAU 2026 gives a strong recommendation for vaginal estrogen in postmenopausal women, though its supporting evidence (four meta-analyses, LE 1b) shows a trend toward prevention, with topical estrogen better than placebo and inferior to antibiotics; oral estrogen was ineffective for prophylaxis.[47] Women already on systemic estrogen should still be given vaginal estrogen, and the AUA panel found insufficient evidence to favor one formulation, so use the patient's preferred product.[43] The AUA 2025 panel considers vaginal estrogen appropriate after breast cancer in coordination with the oncologist.[1][43][47]

Mechanism​

Hypoestrogenic genitourinary changes can contribute to rUTI in postmenopausal women. Estrogen deprivation leads to vaginal and urethral atrophy, loss of Lactobacillus colonization, rising vaginal pH, and increased uropathogen colonization, and vaginal estrogen reverses all three.[5]

Formulations and prescribing​

Use the vaginal estrogen hub for formulation-specific loading, maintenance and labels. Low-dose vaginal estradiol creams, inserts and the local ring have different regimens; a systemic vaginal ring is not an interchangeable substitute. Prasterone is not estrogen and is not an established rUTI-prevention substitute.

Efficacy​

  • Raz & Stamm 1993 (landmark RCT, intravaginal estriol): cumulative infection-free proportion dramatically higher versus placebo over 8 months; the trial that established the modality[6]
  • Chen 2021 meta-analysis (8 RCTs, n = 4,702): in five trials (n = 1,936), vaginal estrogen reduced rUTI with RR 0.42 (95% CI 0.30–0.59); three oral-estrogen RCTs (n = 2,766) found no statistically significant reduction (RR 1.11; 95% CI 0.92–1.35), and NICE advises against systemic hormone therapy solely for rUTI prevention[7][53]
  • Tan-Kim 2023 (retrospective before/after, n = 5,638 women prescribed vaginal estrogen for rUTI): UTI frequency was 51.9% lower in the year after prescription (3.9 to 1.8 episodes/year; p < 0.001).[8]

Safety​

Local irritation and spotting can occur; absorption depends on product and dose. A history of breast cancer requires individualized counseling and, particularly during aromatase-inhibitor therapy, coordination with oncology. Persistent or recurrent postmenopausal bleeding needs evaluation. Use the estrogen hub for current product-label and endometrial-safety details.

See GSM for the clinical framework and the estrogen hub for July 2026 TAPER application evidence and current product-label counseling.

Methenamine hippurate​

AUA/CUA/SUFU 2025 (statement 15): methenamine hippurate may be offered for prophylaxis in women with rUTI .[43] This was added in 2025; it was not an endorsement in the 2022 version. EAU 2026 is stronger: it recommends methenamine hippurate to reduce recurrent cystitis in women without abnormalities of the urinary tract, matching the Cochrane subgroup finding below.[43][47]

Mechanism: methenamine releases formaldehyde in acidic urine; benefit from routine acidification is unproven.[44]

Urine pH and vitamin C​

  • Do not routinely add vitamin C to methenamine. The AUA 2025 discussion advises against the combination because urinary acidifiers have not reliably lowered urine pH or enhanced methenamine efficacy.[43]
  • ALTAR did not test the added value of acidification.[10]
  • The US label advises attention to urinary pH and clinical response, review of alkalinizing foods or medicines, and supplemental acidification only if necessary. The US label sets no numeric urine-pH target.[44]
  • Cranberry is not an established replacement acidifier. An older crossover study in catheterized patients found no additional benefit from cranberry added to methenamine/ascorbic acid; its population and methenamine-mandelate formulation differ from ALTAR. See the cranberry section for its separate prevention evidence.[45]

Formaldehyde was long believed to be resistance-proof because it denatures proteins non-specifically. Hodgkinson 2026 analyzed E. coli isolates from the ALTAR trial and identified formaldehyde-detoxification resistance (FDHR): 11 of 191 sequenced isolates from five participants (5.8%) grew in > 1 mM formaldehyde via non-functional FrmR repressor variants or plasmid-encoded frmA homologues; four participants were in the methenamine arm, while the fifth had a resistant baseline isolate in the nitrofurantoin arm, and clinical significance remains undefined.[40]

Dosing​

  • Standard regimen: 1 g PO BID (adults and patients > 12 years). Use after treatment of an active infection; it is not an acute-UTI treatment.[44]
  • Trials studied 6–12 months; reassess benefit, adverse effects, and breakthrough infections.[10][12]
  • NICE NG112 (December 2024) considers methenamine as an alternative to daily antibiotics for nonpregnant women whose recurrent UTI has not improved with hygiene measures, vaginal estrogen or single-dose prophylaxis. It advises specialist advice for pregnancy, men, children, recurrent upper UTI and complicated lower UTI (some of these are off-label uses), reviewing treatment within 6 months and then every 12 months, and avoiding over-the-counter citrate sachets that alkalinize urine while on methenamine.[53]

Efficacy​

  • ALTAR trial (Harding 2022; 240 randomized, 205 in the primary modified intention-to-treat analysis; multicenter open-label non-inferiority RCT): methenamine was non-inferior to daily low-dose antibiotics (nitrofurantoin 50–100 mg, trimethoprim 100 mg, or cefalexin 250 mg) for symptomatic, antibiotic-treated UTI over 12 months (1.38 versus 0.89 episodes/person-year; within the prespecified 1-episode/person-year margin).[10][11] Among participants whose optional perineal swabs yielded E. coli, resistance to at least one antibiotic at 6 or 12 months was higher in the antibiotic arm (46/64, 72%) than in the methenamine arm (39/70, 56%; p = 0.05); at month 18, multidrug resistance was 9/45 (20%) in the methenamine arm versus 2/39 (5%) in the antibiotic arm (p = 0.06)[10][11]
  • ImpresU trial (Heltveit-Olsen 2025, 289 recruited / 281 analyzed women ≥ 70 y, triple-blind placebo-controlled phase IV): 25% reduction in antibiotic-treated UTIs at 6 months (IRR 0.75; 95% CI 0.57–1.0; p = 0.049); rebound increase in UTI rate after discontinuation (IRR 1.7; 95% CI 1.3–2.3; p < 0.001). Discuss recurrence after stopping and reassess.[12]
  • Lee 2012 Cochrane review (13 studies, n = 2,032): methenamine may reduce symptomatic UTI in patients without renal-tract abnormalities (RR 0.24; 95% CI 0.07–0.89), while benefit was not established in those with known renal-tract abnormalities (RR 1.54; 95% CI 0.38–6.20); the authors separately concluded it did not appear to work in neuropathic bladder[41]
  • Davidson 2024 systematic review (7 studies)[13]

Special populations​

  • Neurogenic bladder / SCI. ALTAR excluded neuropathic bladder. The SINBA placebo-controlled trial in SCI did not show longer time to symptomatic UTI with methenamine. Evaluate the bladder-management program and structural causes of recurrence.[10][46]
  • Renal transplant recipients. A small retrospective series reported fewer UTIs and admissions with methenamine plus vitamin C. Review renal function and concurrent prophylaxis with the transplant team; do not combine with TMP-SMX.[42][44]

Safety​

  • The US label contraindicates renal insufficiency, severe hepatic insufficiency, and severe dehydration. It supplies no numerical eGFR or CrCl cutoff; a research eligibility cutoff must not be substituted for the label.[44]
  • Do not combine with sulfonamides, including TMP-SMX, because of urinary precipitation with formaldehyde. Check the breakthrough-UTI treatment plan as well as daily prophylaxis.[44]
  • Alkaline urine may impair activity, particularly with urease-producing organisms.[44] Persistent or recurrent Proteus infection warrants reassessment.[44]
  • Label-reported adverse effects include nausea, stomach upset, dysuria, and rash; excessive doses can irritate the bladder and cause hematuria. The branded tablet contains tartrazine. The label advises periodic liver-function tests, particularly with hepatic dysfunction.[44]

Cranberry products​

Mechanism: proanthocyanidins (PAC), especially A-type PACs, inhibit P-fimbriae-mediated adherence of uropathogenic E. coli to uroepithelial cells. B-type PACs (apple juice, grape juice, chocolate) lack this anti-adhesion property.[30]

Dose — PAC content matters more than form​

  • WikiGuidelines 2024 gives a clear recommendation for cranberry products containing 36 mg PAC in women with recurrent UTI, children, and people susceptible to UTI after interventions, and finds the evidence insufficient for older adults, bladder-emptying problems, and pregnancy.[2] The AUA 2025 text reaches the same practical figure, a supplement standardized to at least 36 mg of bioavailable PAC, as its discussion of a reasonable option (statement 13, Moderate / Grade B).[43] For children, the EAU 2026 paediatric guideline cites a meta-analysis of randomized trials in which cranberry reduced UTI recurrence versus placebo in children with a normal urinary tract (moderate-quality evidence). It gives a weak recommendation to consider dietary supplements as an alternative or add-on preventive measure in selected cases, and does not consider any supplement ready for routine use.[52] EAU 2026 gives a strong recommendation to advise cranberry products while telling patients the evidence is low quality and contradictory, and states there is no clear evidence on dose or duration.[47]
  • Juice, capsules, and whole-fruit powder have all been studied; a standardized capsule with declared PAC content is the most reproducible form. Cranberry products are regulated as dietary supplements, not drugs; PAC content and quality vary considerably between brands.[30]
  • Whole-fruit powder mass is not interchangeable with PAC content; check the studied product and declared assay or content. The AUA 2025 review reports a PAC content of 0.56% for a whole-fruit powder given at 500 mg/day, which is roughly 3 mg PAC per day by calculation and far below 36 mg[43]
  • Estimated PAC doses in the Cochrane tablet, capsule and powder trials ranged from 1.4 to 120 mg/day, and juice trials reached higher intakes.[30] Pooled by dose, each stratum showed little or no difference from placebo with wide intervals (low, <40 mg/day: RR 0.75, 95% CI 0.52–1.08; moderate, 40–80 mg/day: RR 0.74, 95% CI 0.41–1.31; high, >80 mg/day: RR 1.47, 95% CI 0.91–2.39), and head-to-head dose comparisons were very low certainty.[30]

Efficacy​

The 2023 Cochrane review (Williams, 50 RCTs, 8,857 participants) is the comprehensive synthesis, and the benefit is population-specific:[30]

PopulationRR (95% CI)Certainty
Women with recurrent UTI0.74 (0.55–0.99)Moderate
Children0.46 (0.32–0.68)Moderate
Susceptible after an intervention0.47 (0.37–0.61)Low
Elderly institutionalized0.93 (0.67–1.30)Moderate — benefit not demonstrated
Pregnant women1.06 (0.75–1.50)Moderate — benefit not demonstrated
Neurogenic bladder0.97 (0.78–1.19)Low — benefit not demonstrated
  • Analyzed specifically as tablets / powder, cranberry reduced UTI risk in women with rUTI by approximately 55% (RR 0.45; 95% CI 0.28–0.72; 3 studies, n = 333)[30]
  • Stonehouse 2025 (multicenter, double-blind, placebo-controlled, n = 150 women with rUTI): whole cranberry fruit powder 500 mg/day reduced culture-confirmed UTI by 52% (aRR 0.48; 95% CI 0.26–0.87; p = 0.01), delayed time to first UTI (HR 0.36; p = 0.01), and reduced total episodes (IRR 0.41; p = 0.01)[14]
  • In two trials (n = 385; women with recurrent UTI and children), cranberry versus antibiotics had an imprecise estimate for symptomatic, culture-verified UTI (RR 1.03; 95% CI 0.80–1.33). In three trials (n = 215; children and adults), cranberry may have reduced this outcome versus probiotics (RR 0.39; 95% CI 0.27–0.56).[30]
  • Xia 2021 meta-analysis with trial sequential analysis (23 trials, n = 3,979) reported a pooled RR of 0.70 (95% CI 0.59–0.83) in susceptible populations, including patients with indwelling catheters (RR 0.49).[31]
  • Beerepoot 2013 meta-analysis: pooled RR 0.53 (95% CI 0.33–0.83)[9]
  • NICE NG112 (2018 recommendations, retained in the December 2024 update) says only that women may wish to try cranberry products, that benefit is uncertain and unproven in older women, and that patients should count the sugar in cranberry products or D-mannose toward daily intake. It notes that its D-mannose evidence used 200 mL of a 1% solution (2 g) once daily in the evening.[53]
  • The Juthani-Mehta 2016 nursing-home RCT (two capsules totaling 72 mg PAC daily) found no reduction in bacteriuria-plus-pyuria, consistent with the Cochrane elderly-institutionalized null[32]

Prevention only — not treatment​

A separate Cochrane review found no reliable evidence that cranberry products treat an active UTI. Cranberry is a preventive strategy only.[33]

Safety​

GI adverse effects are possible; the Cochrane review found they probably do not differ from placebo (RR 1.33; 95% CI 1.00–1.77). Supplement composition varies. Review cranberry use with the anticoagulation team when a patient takes warfarin, especially after changing intake.[30][34]

D-mannose​

Mechanism: D-mannose is a monosaccharide (a C-2 epimer of glucose) found naturally in cranberries, grapes, and apples. After oral absorption, a portion of D-mannose enters urine, where it binds the FimH adhesin on the tip of type 1 pili of uropathogenic E. coli, competitively blocking adherence to urothelial mannose receptors so bacteria are voided rather than colonizing. The effect is FimH-specific and primarily relevant to E. coli. Pharmacologically attractive; clinically underwhelming in recent rigorous data.[35]

AUA/CUA/SUFU 2025 (statement 14): inform patients that D-mannose alone may not prevent rUTI .[43] EAU 2026 still lists D-mannose as a weak recommendation, with counseling that the evidence is weak and contradictory; it was written with the MERIT result in view.[43][47]

The AUGS 2025 asymptomatic bacteriuria consensus statement (Q17) lists D-mannose among nonantibiotic options for women with rUTI and intervening ASB, but its literature search ended with 2022 publications and predates MERIT.[51]

Evidence — conflicting​

The evidence splits sharply between earlier open-label trials and the larger blinded RCT:

  • Kranjčec 2014: open-label 3-arm RCT (n = 308) in women with acute cystitis and rUTI history: 6-month recurrence 14.6% (D-mannose 2 g/day) versus 20.4% (nitrofurantoin 50 mg/day) versus 60.8% (no prophylaxis)[36]
  • Porru 2014: randomized crossover (n = 60): mean time to recurrence 200 days (D-mannose) versus 52.7 days (co-trimoxazole)[37]
  • Lenger 2020 meta-analysis: pooled RR 0.23 (95% CI 0.14–0.37; 125 D-mannose recipients and 123 controls) versus no prophylaxis, from the Kranjčec RCT and a prospective cohort; the Porru crossover study contributed to the separate antibiotic comparison[38]
  • Han 2025 network meta-analysis: largest single-agent effect among non-antibiotic interventions (RR 0.34; 95% CI 0.21–0.56; only a cranberry-probiotic-vitamin A triple combination ranked higher), again weighted by smaller / older studies[4]
  • MERIT RCT (Hayward 2024, JAMA Intern Med): double-blind, placebo-controlled, 598 women with rUTI randomized from UK primary care; among 583 with primary-outcome data, 150/294 (51.0%) versus 161/289 (55.7%) contacted ambulatory care for a clinically suspected UTI over 6 months (primary-outcome risk difference −5 percentage points; 95% CI −13 to 3), with no significant difference in symptom burden, time to next UTI, or antibiotic courses; days of prescribed antibiotics favored D-mannose (adjusted median difference −3.0 days, 95% CI −4.4 to −1.6), a finding sensitive to high-use outliers, and similar results across pre-/postmenopausal subgroups[16]
  • WikiGuidelines 2024 concludes insufficient evidence to recommend for or against[2]

Reconciling the discrepancy: the favorable trials were open-label (vulnerable to expectation effects on symptom reporting and healthcare-seeking), enrolled women at the point of active cystitis, and recruited from specialist urology clinics; MERIT was blinded, enrolled women with a history of recurrent UTI, and recruited from primary care. A 2026 review proposed setting-specific use, but no responder subgroup is validated; counseling includes the negative blinded evidence.[39][43]

Dosing (when used despite the equivocal evidence)​

No standardized dose; early pilot studies tested about 200 mg to 2–3 g of D-mannose, with regimens varying by study.[35] Typical regimen 2 g PO once daily or 1 g BID dissolved in water (the 2 g/day dose used in both Kranjčec and MERIT).[16][43]

Safety​

Generally well tolerated; diarrhea is the most common adverse event, with rare vaginal burning.[35] MERIT reported 20 serious adverse events with D-mannose and 8 with placebo; none were judged treatment related.[16] Adverse-event reporting in D-mannose trials was sparse, and glycemic effects during prophylaxis in patients with diabetes have not been established.[35]

Prevention only — not treatment​

The Cochrane review found no reliable evidence that D-mannose treats an active UTI.[35]

Hydration (≥1.5 L/day increase)​

Hooton 2018 (JAMA Intern Med, RCT, n = 140 premenopausal women with rUTI and low baseline fluid intake): adding 1.5 L of water daily (three 500 mL bottles) cut recurrences by approximately 50% over 12 months (1.7 versus 3.2 episodes; p < 0.001) and reduced antimicrobial regimen use comparably.[17] The trial was open-label. WikiGuidelines 2024 found the evidence too limited for a clear recommendation, but judged it reasonable to offer an additional 1.5 L of water to women with recurrent UTI pending a confirmatory study.[2] AUA 2025 (statement 16): for women drinking less than 1.5 L/day, clinicians may offer increased water intake (Conditional / Grade C); EAU 2026 gives a weak recommendation for premenopausal women.[17][43][47]

  • Low-risk, zero-resistance-pressure intervention
  • Respect fluid restrictions

Probiotics​

Evidence varies by strain, route, and population. In a four-arm blinded RCT of 174 premenopausal women with recurrent UTI, four-month symptomatic-UTI incidence was 70.4% with placebo, 61.3% with oral probiotic, 40.9% with vaginal lactobacilli, and 31.8% with combined oral and vaginal probiotics.[54] The Han 2025 network meta-analysis found RR 0.69 (95% CI 0.50–0.94) with the strongest signal in pediatric subgroups (RR 0.50; 95% CI 0.28–0.89).[4] WikiGuidelines 2024 found inconclusive evidence and makes no formal recommendation.[2] The EAU 2026 paediatric guideline reports that a meta-analysis could not demonstrate a benefit of probiotics in children and advises using them only as an adjuvant to antibiotic prophylaxis.[52] The AUA 2025 panel could not recommend Lactobacillus products because of the small number of trials and strain heterogeneity, whereas EAU 2026 weakly advises local or oral probiotics with strains of proven efficacy for vaginal flora regeneration (L. rhamnosus GR-1, L. reuteri B-54 and RC-14, L. casei shirota, L. crispatus CTV-05; LE 1b, a trend toward preventing recurrence).[43][47]

Xyloglucan and herbal combinations. EAU 2026 also weakly advises a xyloglucan-hibiscus-propolis combination, or the herbal combination of Centaurii herba, Levistici radix and Rosmarini folium, to reduce recurrent cystitis and antibiotic use. The EAU cites a meta-analysis of three RCTs (n = 178) for the xyloglucan combination in acute-cystitis treatment studies; its pooled endpoint was clinical or microbiological success (cure or improvement at the end of treatment, or microbiological resolution), and a small RCT (n = 90) in which the herbal combination was added to antimicrobial therapy and recurrence was assessed at 6 and 12 months; neither appears in the AUA 2025 recommendations.[47]

  • Most studied strains: vaginal Lactobacillus crispatus CTV-05 (Lactin-V), L. rhamnosus GR-1, L. reuteri RC-14

Immunoprophylaxis​

These products are not FDA-approved in the US. EAU 2026 weakly recommends immunomodulatory prophylaxis only in a well-regulated clinical trial (it downgraded a previous strong recommendation because of low-certainty data and agent-to-agent heterogeneity; OM-89 and MV140 are the most studied, with MV140 most promising but supported by a single trial that randomized 240 women across three arms, while the EAU's agent-specific placebo estimate cites 146 participants[48]); older regional recommendations have a different evidence date and context. The AUA 2025 panel could not recommend immunoactive agents (or intravesical HA/CS) because trials were few and small.[43][47]

OM-89 (Uro-Vaxom) — oral E. coli lysate​

  • Bauer 2005 RCT (n = 453, multicenter double-blind): 34% reduction in UTI rate (0.84 versus 1.28 episodes; p < 0.003) with favorable safety[18]
  • Beerepoot 2013 meta-analysis: pooled RR 0.61 (95% CI 0.48–0.78)[9]
  • Volontè 2025 systematic review: describes favorable studies; heterogeneous results and the EAU 2026 weak recommendation to use immunomodulatory prophylaxis for women only within a well-regulated clinical trial limit generalization[19][47]
  • Older Latin American consensus. Grade A recommendation[20]
  • Regimen (OM-89 study): 6 mg PO once daily for 90 days; Bauer then gave one capsule daily on the first 10 days of months 7, 8 and 9[18][22]

MV140 (Uromune) — sublingual polybacterial spray​

  • Whole-cell heat-inactivated E. coli, K. pneumoniae, P. vulgaris, E. faecalis
  • Lorenzo-Gómez 2021 frail-elderly cohort reported fewer episodes after treatment.[21]
  • A completed industry-funded randomized trial (2022) enrolled 240 women; among 215 in the protocol-defined analysis population, the median was 0 UTIs with either three or six months of MV140 versus 3 with placebo during the nine-month efficacy period. In that 215-person analysis population, UTI-free proportions over nine months were 39/70 (56%), 40/69 (58%) and 19/76 (25%), respectively.[48]

Urovac — vaginal mucosal vaccine​

  • Modest reduction (RR 0.75; 95% CI 0.63–0.89); primary immunization followed by booster immunization lengthened time to reinfection in the trials pooled by Beerepoot[22][9]

Aziminia 2019 systematic review — 10 RCTs, n = 1,537​

Pooled RR 0.74 (95% CI 0.67–0.81) for vaccines versus placebo; evidence quality low with substantial heterogeneity.[22]

Vitamin D​

Mechanism: vitamin D induces cathelicidin (LL-37), a cationic antimicrobial peptide expressed by bladder urothelium and neutrophils.[23]

Evidence​

  • Jorde 2016 (RCT, n = 511 prediabetic subjects): vitamin D3 20,000 IU/week for 5 years significantly reduced self-reported UTI versus placebo (18 versus 34 subjects; p < 0.02; strongest in men; secondary outcome from questionnaires)[24]
  • D-Health Trial (Pham 2022, n = 21,315 older Australian adults): the overall antibiotic-prescription endpoint was not significantly reduced (IRR 0.98; 95% CI 0.95–1.01); a favorable subgroup used predicted low vitamin D status.[25]
  • Han 2025 network meta-analysis: RR 0.46 (95% CI 0.27–0.81) in the long follow-up subgroup (≥1 year)[4]

Not yet in major rUTI guideline recommendations. Correct established deficiency for its usual indications; do not prescribe high-dose vitamin D solely as proven rUTI prevention.

Intravesical GAG replenishment (HA ± CS)​

Intravesical hyaluronic acid ± chondroitin sulfate is intended to restore the protective GAG layer of the bladder urothelium, reducing bacterial adherence and neurogenic inflammation. Primarily European practice; primarily deployed in refractory rUTI when non-antibiotic and antibiotic strategies have failed.

Evidence​

  • Damiano 2011 placebo-controlled RCT (n = 57): HA-CS instillation reduced UTI rate by 86.6% versus 9.6% placebo (p = 0.0002) and extended time to first recurrence (185 versus 53 days; p < 0.001)[26]
  • Corona 2026 meta-analysis: HA-CS reduced infection rates versus placebo or standard care (OR 0.42; 95% CI 0.25–0.49; p < 0.001)[27]
  • The 2026 Kwon review found an imprecise pooled HA–CS effect (RR 0.41; 95% CI 0.04–4.77) and a favorable but highly heterogeneous HA-alone estimate (RR 0.15; 95% CI 0.05–0.43), based predominantly on observational studies.[29] EAU 2026 found randomized evidence only for HA–CS.[29][47] EAU 2026 weakly recommends HA or HA-CS instillation when less invasive approaches have failed.[47]
  • Goddard 2018 systematic review and meta-analysis (2 randomized and 6 nonrandomized studies): HA ± CS decreased UTI rate per patient-year (pooled MD −2.56; 95% CI −3.86 to −1.26; p < 0.001)[28]

Practical notes​

  • Typical regimen: weekly instillation × 4, then monthly maintenance; protocol varies by product
  • Commercial products include iAluril (HA-CS), Cystistat (HA), Uracyst (CS)
  • Cross-covered in detail in Intravesical IC/BPS agents; same molecules used for bladder pain syndrome

Intravesical aminoglycoside instillation​

Intravesical gentamicin or amikacin is antibiotic treatment delivered locally, included here as an alternative to systemic prophylaxis. It is an off-label, specialist option for selected refractory cases, particularly patients already catheterizing.

  • Kwon 2026 systematic review and meta-analysis: intravesical aminoglycoside instillation was associated with fewer recurrences across six nonrandomized studies (IRR 0.23; 95% CI 0.15–0.37). These studies used baseline or control comparators. The review reported low measured systemic exposure and few adverse events, but called for larger standardized RCTs[29]

Practical notes​

Use a pharmacy-verified local regimen with explicit dose, dilution, dwell time, catheter technique and reassessment. Published regimens differ. The AUA NLUTD guideline allows bladder instillation for CIC users with recurrent UTI as Expert Opinion.[49]

Systemic absorption is usually low but not guaranteed absent: a long-term cohort found one detectable level during macroscopic hematuria after bladder biopsy. Consider mucosal injury, renal function, exposure and local monitoring policy. Obtain cultures for symptomatic breakthrough episodes and use a defined resistance-surveillance plan without treating asymptomatic bacteriuria automatically.[50]

Behavioral modifications​

Review spermicide exposure and baseline water intake. Address clinically relevant incomplete emptying or bowel dysfunction. EAU advises counseling on insufficient hydration, habitual or post-coital delayed urination, wiping back to front, douching and occlusive underwear before long-term prophylaxis, while acknowledging limited evidence, whereas AUA notes that wiping direction and pre/post-coital voiding have not been shown to prevent rUTI.[15][17][43][47]

Evidence Summary​

InterventionStrength of evidenceEffect sizeGuideline status
Vaginal estrogenModerate (meta-analysis of RCTs)RR 0.42 (5 vaginal-estrogen RCTs)AUA 2025 Moderate / Grade B; EAU 2026 strong[7][43][47]
Methenamine hippurateNon-inferiority RCT + placebo-controlled phase IV RCTALTAR met its prespecified margin; ImpresU studied older womenAUA 2025 Conditional / Grade C; EAU 2026 strong (no urinary tract abnormality)[10][12][43][47]
Cranberry (36 mg PAC guideline figure)Moderate (multiple RCTs)Cochrane rUTI subgroup RR 0.74AUA 2025 Moderate / Grade B; EAU 2026 strong with low-quality-evidence counseling; product variability[30][43][47]
Hydration +1.5 L/dayLow (single RCT)Mean 1.7 versus 3.2 cystitis episodes over 12 months in premenopausal women with rUTI drinking <1.5 L/day at baselineAUA 2025 Conditional / Grade C (intake below 1.5 L/day); EAU 2026 weak; WikiGuidelines: reasonable to offer, no clear recommendation[2][17][43][47]
D-mannoseConflicting (network meta positive; largest RCT negative)RR 0.34 for UTI incidence in the network meta-analysis whole group; no significant benefit for medically attended suspected UTI in MERIT women with rUTIAUA 2025: inform that it may not work (Moderate / Grade B); EAU 2026 weak; WikiGuidelines insufficient evidence[4][16][43][47]
ProbioticsLow / inconclusiveRR 0.69 for UTI incidence in Han’s whole-group, mixed-population analysisWikiGuidelines inconclusive[4][2]
OM-89 (Uro-Vaxom)Four RCTs in a 2013 meta-analysis; EAU 2026 agent-specific placebo comparison was not statistically significantRR 0.61 (95% CI 0.48–0.78) in the 2013 meta-analysisOlder Latin American Grade A; EAU 2026 weak recommendation only within a well-regulated trial; not FDA-approved[9][18][19][20][47]
MV140 (Uromune)One placebo-controlled RCT plus cohortsUTI-free over the nine-month efficacy period among 215 protocol-defined analysis participants: 39/70 (56%) after three months of MV140, 40/69 (58%) after six months, versus 19/76 (25%) with placeboEAU trial-only; not FDA-approved[47][48]
Vitamin DLow (limited RCTs)RR 0.46 in long-follow-up subgroupNot in major guidelines[4][24]
Intravesical HA ± CSLow–moderate (small RCTs, meta-analysis)HA–CS in randomized trials: infection-rate OR 0.42; HA ± CS across randomized and nonrandomized studies: MD −2.56 UTIs per patient-yearRefractory-rUTI option (mainly European)[27][28]
Intravesical aminoglycosidesLow (six nonrandomized studies pooled)IRR 0.23 versus baseline or controlSelected refractory cases; heterogeneous protocols[29]
Behavioral counselingIntervention-specificHydration evidence applies to low-volume drinkersHygiene rituals are not established prevention

Clinical Positioning​

  • Vaginal estrogen is first-line in postmenopausal women with rUTI regardless of whether GSM symptoms are the presenting complaint; the 2023 Tan-Kim real-world data (51.9% reduction, n = 5,638) and Chen meta-analysis (RR 0.42) are the anchor evidence.[7][8]
  • Systemic estrogen has no role in UTI prevention; use vaginal routes only.[7]
  • Discuss methenamine as an alternative to daily antibiotic prophylaxis for eligible women with rUTI. ALTAR met a one-UTI/person-year non-inferiority margin. Do not add routine vitamin C.[10][11][43]
  • Offer cranberry as an option, explaining uncertain optimal PAC dose and product variability.[2][14]
  • D-mannose is no longer routinely recommended. The MERIT primary-care RCT (598 women, double-blind, placebo-controlled) was negative.[16]
  • Consider increased water for low-volume drinkers; Hooton enrolled premenopausal women drinking less than 1.5 L/day.[17]
  • Immunoprophylaxis requires jurisdiction-specific review; EAU 2026 weakly recommends immunomodulatory prophylaxis for women only within a well-regulated clinical trial[47], and these products are not FDA-approved in the US.[19][20][21]
  • Correct vitamin D deficiency for standard indications, without claiming proven UTI prevention.[4][23][24]
  • Intravesical therapy (HA/CS, aminoglycoside) is for refractory rUTI. Escalate to this tier when oral non-antibiotics and appropriate antibiotic strategies have failed. The 2026 Kwon review supports further study of aminoglycosides (IRR 0.23).[29]
  • Discuss useful behavioral measures without hygiene blame. Spermicide avoidance and hydration assessment have a different evidence basis from wiping direction or postcoital voiding.

See Also​

References​

1. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

2. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

3. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

4. Han Z, Yi X, Li J, Liao D, Ai J. "Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials." Infection. 2025;53(2):535–546. doi:10.1007/s15010-024-02357-z

5. Buck ES, Lukas VA, Rubin RS. "Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause." Urology. 2021;151:31–36. doi:10.1016/j.urology.2020.05.058

6. Raz R, Stamm WE. "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections." N Engl J Med. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102

7. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

8. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

9. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. "Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials." J Urol. 2013;190(6):1981–1989. doi:10.1016/j.juro.2013.04.142

10. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial (ALTAR)." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

11. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

12. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025;31(11):1873–1879. doi:10.1016/j.cmi.2025.07.006

13. Davidson SM, Brown JN, Nance CB, Townsend ML. "Use of methenamine for urinary tract infection prophylaxis: systematic review of recent evidence." Int Urogynecol J. 2024;35(3):483–489. doi:10.1007/s00192-024-05726-2

14. Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD. "Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: a 6-month multicenter, randomized, double-blind, placebo-controlled trial." Am J Clin Nutr. 2025;121(4):932–941. doi:10.1016/j.ajcnut.2025.01.022

15. Schmiemann G, Kranz J, Mandraka F, et al. "The diagnosis, treatment, and prevention of recurrent urinary tract infection." Dtsch Arztebl Int. 2024;121(11):373–382. doi:10.3238/arztebl.m2024.0068

16. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

17. Hooton TM, Vecchio M, Iroz A, et al. "Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial." JAMA Intern Med. 2018;178(11):1509–1515. doi:10.1001/jamainternmed.2018.4204

18. Bauer HW, Alloussi S, Egger G, et al. "A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections." Eur Urol. 2005;47(4):542–548. doi:10.1016/j.eururo.2004.12.009

19. Volontè S, De Vicari D, Cola A, Barba M, Frigerio M. "Efficacy and safety of Uro-Vaxom in urinary tract infection prevention: a systematic literature review." J Clin Med. 2025;14(11):3836. doi:10.3390/jcm14113836

20. Haddad JM, Ubertazzi E, Cabrera OS, et al. "Latin American consensus on uncomplicated recurrent urinary tract infection — 2018." Int Urogynecol J. 2020;31(1):35–44. doi:10.1007/s00192-019-04079-5

21. Lorenzo-Gómez MF, Padilla-Fernández B, Flores-Fraile J, et al. "Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly." Vaccine. 2021;39(42):6308–6314. doi:10.1016/j.vaccine.2021.08.093

22. Aziminia N, Hadjipavlou M, Philippou Y, et al. "Vaccines for the prevention of recurrent urinary tract infections: a systematic review." BJU Int. 2019;123(5):753–768. doi:10.1111/bju.14606

23. Hertting O, Holm Å, Lüthje P, et al. "Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder." PLoS One. 2010;5(12):e15580. doi:10.1371/journal.pone.0015580

24. Jorde R, Sollid ST, Svartberg J, et al. "Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects." Infect Dis (Lond). 2016;48(11–12):823–828. doi:10.1080/23744235.2016.1201853

25. Pham H, Waterhouse M, Baxter C, et al. "Vitamin D supplementation and antibiotic use in older Australian adults: an analysis of data from the D-Health Trial." J Infect Dis. 2022;226(6):949–957. doi:10.1093/infdis/jiac279

26. Damiano R, Quarto G, Bava I, et al. "Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial." Eur Urol. 2011;59(4):645–651. doi:10.1016/j.eururo.2010.12.039

27. Corona G, Capogrosso P, Baldini S, et al. "Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis." BJU Int. 2026;137(1):36–48. doi:10.1111/bju.70016

28. Goddard JC, Janssen DAW. "Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis." Int Urogynecol J. 2018;29(7):933–942. doi:10.1007/s00192-017-3508-z

29. Kwon M, Ahmad A, Lott N, Blatt A. "Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis." BJU Int. 2026;138(1):33–44. doi:10.1111/bju.70252

30. Williams G, Stothart CI, Hahn D, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023;11:CD001321. doi:10.1002/14651858.CD001321.pub7

31. Xia JY, Yang C, Xu DF, et al. "Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: a systematic review and meta-analysis with trial sequential analysis." PLoS One. 2021;16(9):e0256992. doi:10.1371/journal.pone.0256992

32. Juthani-Mehta M, Van Ness PH, Bianco L, et al. "Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial." JAMA. 2016;316(18):1879–1887. doi:10.1001/jama.2016.16141

33. Jepson RG, Mihaljevic L, Craig JC. "Cranberries for treating urinary tract infections." Cochrane Database Syst Rev. 2023;12:CD001322. doi:10.1002/14651858.CD001322.pub2

34. Madden E, McLachlan C, Oketch-Rabah H, Calderón AI. "Safety of cranberry: evaluation of evidence of kidney stone formation and botanical drug-interactions." Planta Med. 2021;87(10-11):803–817. doi:10.1055/a-1497-6241

35. Cooper TE, Teng C, Howell M, et al. "D-mannose for preventing and treating urinary tract infections." Cochrane Database Syst Rev. 2022;8:CD013608. doi:10.1002/14651858.CD013608.pub2

36. Kranjčec B, Papeš D, Altarac S. "D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial." World J Urol. 2014;32(1):79–84. doi:10.1007/s00345-013-1091-6

37. Porru D, Parmigiani A, Tinelli C, et al. "Oral D-mannose in recurrent urinary tract infections in women: a pilot study." J Clin Urol. 2014;7(3):208–213. doi:10.1177/2051415813518332

38. Lenger SM, Bradley MS, Thomas DA, et al. "D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis." Am J Obstet Gynecol. 2020;223(2):265.e1–265.e13. doi:10.1016/j.ajog.2020.05.048

39. Munir A, Tarannum T, Saad N, Abdaal M. "Effectiveness of non-antibiotic therapies in the management of recurrent urinary tract infections in women: a systematic review." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06654-z

40. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

41. Lee BS, Bhuta T, Simpson JM, Craig JC. "Methenamine hippurate for preventing urinary tract infections." Cochrane Database Syst Rev. 2012;10:CD003265. doi:10.1002/14651858.CD003265.pub3

42. Hollyer I, Varias F, Ho B, Ison MG. "Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: a single center, retrospective study." Transpl Infect Dis. 2019;21(3):e13063. doi:10.1111/tid.13063

43. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)." J Urol. 2026;215(1):3–12. doi:10.1097/JU.0000000000004723. Full guideline, statements 13–16 and 20.

44. Validus Pharmaceuticals LLC. HIPREX (methenamine hippurate tablets USP): US prescribing information. July 2021; DailyMed record revised February 2022. Prescribing information. Accessed September 11, 2026.

45. Nahata MC, Cummins BA, McLeod DC, Schondelmeyer SW, Butler R. "Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy." Eur J Clin Pharmacol. 1982;22:281–284. doi:10.1007/BF00545228.

46. Lee BB, Haran MJ, Hunt LM, et al. "Spinal-injured neuropathic bladder antisepsis (SINBA) trial." Spinal Cord. 2007;45:542–550. doi:10.1038/sj.sc.3101974.

47. European Association of Urology. EAU Guidelines on Urological Infections. 2026. Full guideline.

48. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. 2022. doi:10.1056/EVIDoa2100018.

49. AUA/SUFU. Adult neurogenic lower urinary tract dysfunction: treatment and follow-up. 2021. Statements 37–39. doi:10.1097/JU.0000000000002239.

50. Bilsen MP, van Uhm JIM, Stalenhoef JE, et al. Intravesical aminoglycoside instillations as prophylaxis for recurrent urinary tract infection: patient satisfaction, long-term safety and efficacy. JAC Antimicrob Resist. 2023;5:dlad040. doi:10.1093/jacamr/dlad040.

51. Siddiqui NY, Ackerman AL, Advani SD, et al. "Management of Asymptomatic Bacteriuria in Adult Female Populations." Urogynecology (Phila). 2025;31(9):827–845. doi:10.1097/SPV.0000000000001731

52. European Association of Urology. EAU Guidelines on Paediatric Urology: Urinary Tract Infections in Children (section 12.7). 2026 limited update, March 2026. Guideline.

53. NICE. Urinary tract infection (recurrent): antimicrobial prescribing (NG112). Published October 31, 2018; last updated December 12, 2024. Guideline

54. Gupta V, Mastromarino P, Garg R. "Effectiveness of prophylactic oral and/or vaginal probiotic supplementation in the prevention of recurrent urinary tract infections: a randomized, double-blind, placebo-controlled trial." Clin Infect Dis. 2024;78(5):1154–1161. doi:10.1093/cid/ciad766